PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 15, 2026Annals of Allergy Asthma & Immunology0 citationsOpen Access

Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)

View Full Paper
SCSimon CouillardNPNayia PetousiSRSanjay Ramakrishnan

Key Points

  • Assess the effect of dupilumab on inducing clinical remission in at-risk individuals with type-2 inflammatory asthma.
  • Multinational, investigator-initiated design
  • Parallel group randomised trial
  • Double-blind and placebo-controlled setup
  • Adheres to SPIRIT 2025 guidelines
  • Results will be reported at international meetings
  • Findings will be published in peer-reviewed journals

Abstract

Approved by the Research Ethics Committee of CIUSSS de l'Estrie-CHUS (MP-31-2026-6116). The protocol follows SPIRIT 2025 guidelines. Results will be disseminated at international meetings and in peer-reviewed journals in accordance with CONSORT.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Couillard et al. (2026) studied this question.

synapsesocial.com/papers/69df2a4be4eeef8a2a6af765https://doi.org/10.1016/j.anai.2026.03.028
Ask AI
Helpful
Bookmark
Share
View Full Paper